NWI Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.93M Hold
25,000
0.28% 38
2025
Q4
$4.6M Hold
25,000
0.21% 46
2025
Q3
$3.84M Hold
25,000
0.2% 47
2025
Q2
$3.49M Hold
25,000
0.18% 44
2025
Q1
$3.67M Hold
25,000
0.46% 29
2024
Q4
$3.28M Hold
25,000
0.14% 39
2024
Q3
$3.9M Hold
25,000
0.1% 30
2024
Q2
$3.9M Hold
25,000
0.14% 24
2024
Q1
$3.39M Hold
25,000
0.1% 34
2023
Q4
$3.37M Hold
25,000
0.08% 36
2023
Q3
$3.39M Sell
25,000
-25,000
-50% -$3.41M 0.16% 31
2023
Q2
$7.16M Hold
50,000
1.29% 19
2023
Q1
$6.94M Hold
50,000
0.76% 28
2022
Q4
$6.78M Sell
50,000
-100,000
-67% -$12.5M 1.5% 23
2022
Q3
$16.5M Hold
150,000
2.89% 9
2022
Q2
$19.8M Buy
150,000
+100,000
+200% +$13.1M 1.18% 18
2022
Q1
$6.63M Hold
50,000
0.76% 27
2021
Q4
$5.83M Hold
50,000
0.38% 36
2021
Q3
$6.01M Hold
50,000
0.37% 36
2021
Q2
$5.99M Hold
50,000
0.37% 35
2021
Q1
$4.97M Hold
50,000
0.41% 35
2020
Q4
$5M Buy
+50,000
New +$5.3M 0.5% 31

Other funds holding AZN

NWI Management's AZN Position: Q1 2026 in Review

NWI Management held its AstraZeneca (AZN) position steady in Q1 2026 at 25,000 shares worth $4.93M. The position accounts for 0.28% of the portfolio, ranked #38.

NWI Management first reported a position in AZN in Q4 2020 and has held it in 22 quarters since. The position peaked at $19.8M in Q2 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • NWI Management held 25,000 shares of AstraZeneca worth $4.93M as of Q1 2026.
  • NWI Management left its AstraZeneca share count unchanged in Q1 2026.
  • AstraZeneca made up 0.28% of NWI Management's portfolio in Q1 2026, its #38 holding.
  • NWI Management first reported a position in AstraZeneca in Q4 2020 and has held it in 22 quarters since.
  • NWI Management's AstraZeneca position peaked at $19.8M in Q2 2022.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on NWI Management's 13F filing for Q1 2026, filed 15 May 2026.